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Edited by Masayuki MiyasakaAbstract Transendothelial leukocyte migration is a major as-
pect of the innate immune response. It is essential in repair and
regeneration of damaged tissues and is regulated by multiple cell
adhesion molecules (CAMs) including members of the immuno-
globulin (Ig) superfamily. Activated leukocyte cell adhesion mol-
ecule (ALCAM/CD166) is an Ig CAM expressed by activated
monocytes and endothelial cells. Hitherto, the functional rele-
vance of ALCAM expression by endothelial cells and activated
monocytes remained unknown. In this report, we demonstrate sol-
uble recombinant human ALCAM signiﬁcantly inhibited the rate
of transendothelial migration of monocyte cell lines. Direct
involvement of ALCAM in transendothelial migration was evi-
dent from the robust inhibition of this process by ALCAM block-
ing antibodies. However, soluble recombinant ALCAM had no
impact on monocyte migration or adhesion to endothelium. Local-
ization of ALCAM speciﬁcally at cell–cell junctions in endothelial
cells supported its role in transendothelial migration. This study is
the ﬁrst to localize ALCAM to endothelial cell junctions and dem-
onstrate a functional relevance for co-expression of ALCAM by
activated monocytes and endothelial cells.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Migration of monocytes from circulation to extravascular
tissues is critical for generating tissue monocytes and macro-
phages, which are an integral feature of both innate and adap-
tive immune responses, and the repair process in many tissues.
Monocyte recruitment is a complex process that involves mul-
tiple adhesive interactions with the endothelium [1–3]. Early
stages in this process involve rolling of circulating monocytes
in post capillary venules in the systemic circulation. A margin-
ating pool of monocytes physically deform to transit pulmon-
ary capillary vessels and are therefore routinely slowed-down
in this vascular segment, which is the primary site for their
retention in the lung [4,5].*Corresponding author. Fax: +1 251 460 6771.
E-mail address: soforiac@usouthal.edu (S.F. Ofori-Acquah).
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is followed by markedly stronger adhesion between monocytes
and endothelial cells mediated by leukocyte-speciﬁc b2 inte-
grins and cognate ligands such as intercellular cell adhesion
molecule family members expressed on endothelium. Adherent
monocytes become activated and upregulate expression of sev-
eral adhesion molecules, which promotes their migration
through endothelial junctions, or through the body of endo-
thelial cells in a process called diapedesis. Several adhesion
molecules play important roles in this ﬁnal stage of recruit-
ment. Platelet/endothelial cell adhesion molecule-1 (PECAM-
1) (CD31), is expressed on the surfaces of most leukocytes
and at the borders of endothelial cell contacts, and is required
for monocyte diapedesis [6]. Interestingly, inhibition of PE-
CAM-1 function with blocking antibodies [7] or by genetic
ablation [8] does not eﬀect diapedesis in several vascular beds
including the pulmonary microcirculation [7]. CD99 is ex-
pressed on subsets of leukocytes as well as at endothelial cell
junctions, and has been shown to control the ﬁnal step of
monocyte diapedesis across human umbilical vein endothelial
cell barriers [9]. More recently, the role of junctional adhesion
molecules (JAM) in diapedesis have been documented [10–15].
There is robust recruitment of neutrophils by inﬂamed lungs in
transgenic mice over-expressing endothelial JAM-C [16],
although JAM-C over-expression has no signiﬁcant impact
on monocyte recruitment [16]. These ﬁndings are consistent
with a model whereby diapedesis is tightly controlled at the lo-
cal level by several factors including adhesion molecules teth-
ered at endothelial junctions that exert a unique barrier
phenotype in diﬀerent vascular segments [17].
ALCAM (CD166) is an immunoglobulin (Ig) cell adhesion
molecule consisting of ﬁve extracellular Ig domains, a single
transmembrane domain and a short cytoplasmic tail. It is ex-
pressed by several cell types including endothelial cells, and gi-
ven multiple names including BEN and HB2 [18–21]. ALCAM
is not expressed in peripheral blood monocytes, however, it is
upregulated in activated monocytes [22,23]. The functional rele-
vance of this induction currently remains poorly understood.
ALCAMhasbeen implicated in invasionof endothelial cells into
cartilage [24], implantation of blastocysts [25], neurite out-
growth [26] and invasion of melanoma cells [27]. While each of
these studies implicates ALCAM in cell migration, a similar role
for the molecule in activated monocytes has not previously been
reported. In this study, we show that soluble recombinant AL-blished by Elsevier B.V. All rights reserved.
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migration of THP1 and HL60 monocytes, but had no impact
on migration or adhesion of monocytes to endothelium. Confo-
cal analysis showed localization of ALCAM at endothelial cell
junctions consistent with its speciﬁc role in diapedesis. More-
over, ALCAM-GFP was recruited to cell–cell contacts in live
endothelial cells. These ﬁndings represent the ﬁrst demonstra-
tion of ALCAM’s subcellular localization in endothelial cells
and its role in diapedesis.2. Materials and methods
2.1. Human cell lines
Human monocyte cell lines THP1 (catalog no. TIB-202), HL-60
(catalog no. CCL-240) and U937 (catalog no. CRL-1593) were pur-
chased from American Type Culture Collection (ATCC), Manassas,
VA. The human K562 erythroleukemia cell line was a gift from Dr.
Pace. THP1 cells were cultured in RPMI 1640 medium (ATCC), sup-
plemented with 10% fetal bovine serum (FBS) and 0.05 mM 2-mercap-
toethanol. HL60 cells were cultured in RPMI 1640 medium (ATCC)
containing 10% FBS. HL60 and K562 cells were cultured in Iscove’s
modiﬁed Dubelcco’s medium (IMDM) (ATCC) containing 10% FBS.
2.2. Isolation and culture of primary rat endothelial cells
Pulmonary microvascular endothelial cells (PMVECs) were isolated
and cultured using a modiﬁcation of a method we have previously de-
scribed [28]. Male Sprague-Dawley rats (300–400 g) were euthanized
by intraperitoneal injection of 50 mg of pentobarbital sodium (Nembu-
tal, Abbott Laboratories). After sternotomy, the heart and lungs were
removed en bloc and placed in a DMEM bath containing 90 lg/ml
penicillin and streptomycin. Thin strips were removed from the lung
periphery adjacent to the pleural surface, ﬁnely minced, and trans-
ferred with 2–3 ml DMEM to a 15-ml conical tube containing 3-ml
digestion solution. [0.5 g BSA, 10000 U type 2 collagenase (Worthing-
ton Biochemical Co, Lakewood, NJ), and cmf-PBS (Gibco BRL) to
make 10 ml total volume]. The digestion mixture was allowed to incu-
bate at 37 C for 15 min before pouring through an 80-mesh sieve into
a sterile 200-ml beaker. An additional 5 ml of normal medium [10% fe-
tal bovine serum (FBS), Hyclone, Logan, UT) with 30 lg/ml penicillin
and streptromycin in DMEM] was used to wash the sieve. The isola-
tion mixture was transferred to a 15 ml conical tube and centrifuged
at 300 · g for 5 min, the medium aspirated, and the cells resuspended
with 5 ml complete medium [1 part microvascular conditioned med-
ium: three parts incomplete medium (80% RPMI 1640, 20% FBS,
12.3 U/ml Heparin (Elkins-Sinn, Cherry Hill, NJ), and 6.7 lg/ml
Endogro (Vec Technologies, Rensselaer, NY) with 30 lg/ml penicillin
and streptomycin]. Centrifugation/aspiration was repeated, the cells
resuspended in 2–3 ml complete medium and allowed to incubate at
37 C for 30 min before being placed drop wise onto 35-mm culture
dishes. After 1 h at 37 C with 5% CO2, 3 ml of complete medium
was added. The dishes were checked daily for contaminating cells that
were removed by scraping and aspiration. Endothelial cell colonies
were isolated with cloning rings, trypsinized, resuspended in 100 ll
complete medium and placed as a drop in the center of a T-25 ﬂask.
The cells were allowed to attach (1 h at 37 C with 5% CO2) before
the addition of 5 ml complete medium. Cultures were characterized
using, uptake of 1,1 0-dioctadecyl-3,3,3 0,3 0-tetramethylindocarbocya-
nine-labeled low-density lipoprotein (DiI-acetylated LDL), a lectin-
binding panel and were routinely passaged by scraping [29].
2.3. Chimeric molecules and antibodies
Recombinant human ALCAM-Fc, recombinant mouse ALCAM-Fc
and recombinant human VE-cadherin-Fc chimeric proteins were pur-
chased from R&D Systems (Minneapolis, MN). Generation of rabbit
anti-rat ALCAM antibody BRI-1 has previously been described as
anti-HB2 [21,30]. BRI-1 antiserum was puriﬁed on a protein-A column
(ImmunoPure Plus High Capacity, Pierce Biotechnology, Inc. Rock-
ford, IL). Monoclonal anti-ALCAM antibodies used were anti-human
clone MOG/07 (Novacastra, Newcastle, UK), anti-rat ALCAM clone
2117 (gift from Genetech) and puriﬁed and FITC-labeled anti-human
ALCAM clone J4-81 (Antigenix America, Huntington Station, NY).Horse radish peroxidase (HRP) conjugated antibodies used included
anti-mouse and -rabbit IgG (Santa Cruz Biotech and Jackson Labora-
tories, West Grove, PA). Alexaﬂuor 488 and 594 were from Molecular
Probes, (Eugene, OR). Fab fragments were made by incubating mono-
clonal antibodies with immobilized Papain beads (Pierce, Biotechnol-
ogy, Rockford) for 3 h at 37 C, according to the manufacturer’s
protocol; uncut IgG and Fc fragments were then removed by repeated
passage over Protein G Sepharose. Purity and proper size of IgG and
Fab fragments were conﬁrmed by SDS–PAGE. Anti-human IgG (Fc-
speciﬁc) Fab was purchased from Sigma (St Louis, MO) and FITC-
labeled mouse IgG1 from Antigenix America.
2.4. Flow cytometry
THP1 and HL60 monocytes were washed once in IMDM with 5%
FBS, then resuspended in phosphate buﬀered saline (PBS) containing
0.2% bovine serum albumin (BSA) and 0.1% sodium azide (FACS
buﬀer) with saturating amounts of human Fc receptor block (Miltenyi
Biotech Inc. Auburn, CA). After ﬁve-minute incubation on ice, FITC-
labeled anti-human ALCAM antibody clone J4-81 or an isotype-
matched control (FITC-labeled mouse IgG1) was added to the cells
for 30 min. After 30 min of incubation on ice, cells were washed three
times and then resuspended in FACSbuﬀer and analyzed by ﬂow cytom-
etry (FACScan; Becton Dickinson, Mountain View, CA). Additional
control cell suspensions were incubated with secondary antibody alone.
2.5. Cell fractionation and Immunoblotting
Cell lysates prepared with ice-cold cell lysis buﬀer (Cell Signaling
Technology, Beverly, MA) containing 1% triton X-100 (v/v) and sup-
plemented with 1% protease inhibitor cocktail (Roche, Indianapolis,
IN) was clariﬁed by centrifugation at 13000 rpm for 15 min at 4 C,
and soluble cell fractions harvested. Protein content in cell lysates
was measured using a Lowry protein assay (Sigma). Lysates were com-
bined with Laemmli buﬀer (Sigma), boiled for 2 min and resolved by
electrophoresis on a 10% polyacrylamide gel. Samples were blotted
unto nitrocellulose membranes, probed with antibodies, and protein
bands identiﬁed by chemiluminescence (Fujiﬁlm LAS-1000 imaging
system, FujiFilm, Valhalla, NY).
2.6. Immunostaining
Endothelial cells seeded on glass cover slips were ﬁxed with metha-
nol and blocked with 2% normal goat serum for 10 min, followed by
staining with aﬃnity puriﬁed BRI-1 (1: 200 dilution), and Alexﬂour
594 (1/1000 dilution) (Molecular Probes). Cells were mounted with
Dako Fluorescent mounting media (Dako, Carpinteria, CA). For neg-
ative control, the steps with primary antibody were omitted, and no
speciﬁc immunoreactivity was detected in those slides. Stained cells
were visualized using a laser confocal scanning microscope (Leica
TCS SP2, Leica, Exton, PA) and by epiﬂuorescence (Nikon TE2000,
Nikon Instruments Inc., Melville, NY).
2.7. Cloning and expression of ALCAM-GFP
ALCAM cDNA was ampliﬁed from total RNA isolated from cul-
tured rat PMVECs using gene-speciﬁc primers ﬂanked with recogni-
tion and cleavage sites for Age I and SaI I. (Forward primer;
5 0-TTGTCGGTGGCCTTCTAGGA-30, reverse primer; 5 0-GGCTT-
CTGTTTTGTGATTG-3 0). PCR product was sub-cloned into the
AgeI/SalI site in pRV-CMV-eGFP vector (Applied Vironomics, Fre-
mount, CA). Multiple clones were isolated and veriﬁed by sequence
analysis. For transfection, log-phase growing human K562 cells and
semi-conﬂuent rat PMVECs seeded on glass cover slips were transfec-
ted with ALCAM-GFP plasmid DNA (2.5 lg) using lipofectamine
2000 (Invitrogen). Stable lines of K562-ALCAM-GFP and ALCAM-
GFP were selected with G418 (700 lg/ml) for 20 days. Expression of
ALCAM-GFP was examined by epiﬂuorescence (Nikon TE2000).
MetaMorph premier software was used to obtain z-stacks of K562-
ALCAM-GFP clusters.
2.8. Monocyte–endothelial cell adhesion
PMVECs were grown to conﬂuence in 96-well plates. THP1 mono-
cytes were labeled with 5 lg/ml calcein-AM (Molecular Probes) at
37 C for 20 min, and washed twice with phenol-red free IMDM con-
taining 10% FBS. Fluorescent-labeled THP1 monocytes (104/well)
were added to PMVEC monolayers at 37 C for 30 min in the presence
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washing, adhesion of monocytes was detected by excitation at
490 nm with bandwidth of 5 nm, and emission at 510 nm with a band-
width of 5 nm at 37 C using a bottom reading ﬂuorescent plate reader
(Saﬁre2 Tecan, Salzburg, Austria).
2.9. ALCAM ligand binding
Flat bottom 96-well plates were coated with goat anti-human Fc-
F(ab 0)2 in binding buﬀer (20 mM Tris, 150 mM NaCl, 1 mM CaCl2,
1 mM MgCl2, pH 8.0) for 1 h. Thereafter, the wells were treated with
1% (w/v) bovine serum albumin in binding buﬀer and coated with
500 ng/ml of recombinant human ALCAM-Fc for 1 h. K562 cells
expressing rat ALCAM-GFP or GFP alone (2 · 104) were allowed to
adhere to recombinant human ALCAM-Fc coated plates for 30 min
at 37 C. After washing, adhesion of K562 cells was detected by exci-
tation at 490 nm with bandwidth of 5 nm, and emission at 510 nm with
a bandwidth of 5 nm at 37 C using a bottom reading ﬂuorescent plate
reader (Saﬁre2 Tecan).
2.10. Migration
Fluorescently labeled THP1 monocytes (104) in phenol-red free and
serum-free IMDM (200 ll), in the presence or absence of recombinant
human ALCAM-Fc (25 lg/ml), were added to the upper chamber in
Floroblock transwells inserts with 3 lm pore size. Phenol-red free
and serum-free IMDM (700 ll) with 10 ng/ml of MCP-1 was placed
in the bottom chamber. Migration of THP1 cells to the bottom cham-
ber was detected by excitation at 490 nm with bandwidth of 5 nm, and
emission at 510 nm with a bandwidth of 5 nm at 37 C using a bottom
reading ﬂuorescent plate reader (Saﬁre2 Tecan).
2.11. Transendothelial migration
Endothelial cells (50000/well) were seeded on 3 lm pore-size ﬂuores-
cent blocking membrane inserts (BD Bioscience, Bedford,MA) without
media in the bottom chamber to prevent migration through the pores.
Culture media was changed every three days, and conﬂuent endothelialFig. 1. ALCAM expression by human monocyte cell lines. (A) Lysates of C
extracellular rat ALCAM (Ag 2117) were blotted with anti-ALCAM antibo
lysates with PNGase F reduced the size of mature ALCAM (lane 1) to the exp
ALCAM in human monocyte (THP1, HL60 and U937) and erythroleukemia
protein samples. (D) Flow cytometry identiﬁcation of ALCAM in THP1 m
Histogram in the upper panel are THP1 monocytes labeled with FITC-conju
panel are cells labeled with isotype-matched mouse IgG1 conjugated with FImonolayers gently rinsed with phenol-red free IMDM containing 10%
FBS. The endothelial monolayer was loaded with ﬂuorescently labeled
monocyte cell lines (106) then transferred to fresh Transwell containing
phenol-red-free IMDM with MCP-1 (0–100 ng/ml). Transwells were
incubated at 37 C in a humidiﬁed incubator with 5% CO2, and migra-
tion of monocytes through the endothelium detected as described above
using a bottom reading ﬂuorescent plate reader (Saﬁre2 Tecan).
2.12. Statistics
The data are reported as the means ± S.D. for at least three indepen-
dent experiments. Statistical analysis of the raw data were performed
by two tailed t tests. Student’s t-test was used to measure diﬀerences
in samples of two groups. Probability of less than 0.05 was considered
signiﬁcant.3. Results and discussion
ALCAM is expressed by activated monocytes and endothe-
lial cells however the functional relevance of this co-expression
has not yet been explored. In this work we demonstrated that
ALCAM is required for transmigration of monocyte cell lines,
however, ALCAM was not involved in adhesion of monocytes
to endothelium. These functional data were supported by spe-
ciﬁc localization of ALCAM at cell–cell junctions in endothe-
lial cells.
3.1. ALCAM expression in human monocyte cell lines
We initially evaluated the capacity of several antibodies to
bind extracellular epitopes of ALCAM by analyzing lysates
of Chinese hamster ovary (CHO) cells transfected with plasmid
DNA clone Ag 2117, which encodes extracellular rat ALCAMHO cells transfected with empty vector (vector) or vector expressing
dies BRI-1, 2117 and MOG/07. (B) Treatment of CHO transfectant
ected size of the nascent molecule (lane 2). (C) Western blot analysis of
(K562) cells. Blotting of eEF1a was used to conﬁrm equal loading of
onocytes. Viable cells were gated based on forward and side scatter.
gated mouse anti-human ALCAM (J4-81), and histogram in the lower
TC. MW, molecular weight.
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vealed the presence of a major band of 110 kDa, consistent
with the size of mature ALCAM (Fig. 1A). Parental CHO cells
contained very low level of endogenous ALCAM as has previ-
ously been reported [21]. Fig. 1A shows clearly that this low
level expression had no impact on speciﬁc detection of rat AL-
CAM in the CHO transfectants using BRI-1. There was poor
reactivity with the monoclonal antibodies, J481 and MOG/07
that were raised against human ALCAM (Fig. 1A and data
not shown).
BR-1 reacted strongest and recognized a broad protein band,
which on lighter exposure of the immunoblot membrane re-
vealed two distinct bands (data not shown). Nascent ALCAM
is 70 kDa in size, and is glycosylated to yield a 90–110 kDa
mature molecule, therefore, we considered the possibility that
BRI-1 reacted with various ALCAM species. Transfected
CHO lysates were digested with N-glycosidase PNGase F (pep-
tide-N-glycosidase F), and the digest blottedwith BR-1. A single
major protein band was identiﬁed in the PNGase F digest
(Fig. 1B, lane 2), conﬁrming the speciﬁcity of our antibody,
and previous studies indicating modiﬁcation of ALCAM in-
volves addition of N-linked glycan units [20]. Blotting of PNG-
Ase digested lysates fromparental CHO cells yielded a very faint
band of approximately 70 kDa (data not shown), consistent
with the relatively low-level ALCAM expression in this cell line
(Fig. 1A).
Several myeloid cell lines have been extensively demon-
strated to have monocytic characteristics and are routinely
used as surrogates for activated monocytes. A previous study
of ALCAM mRNA expression revealed ALCAM transcripts
in THP1 and HL60 monocyte lines, but not in the U937 mono-
cyte or K562 erythroleukemia cell lines [23]. ALCAM protein
expression has hitherto not been demonstrated in these cells
therefore, lysates were blotted for ALCAM with anti-human
ALCAM monoclonal antibody MOG/07. A major band of
about 110 kDa was identiﬁed in THP1 and HL60 cells, a faint
band of the same size was surprisingly found in U937 cells
however there was no protein band in K562 cells (Fig. 1C).
Equal loading of protein samples for each cell type was con-
ﬁrmed by the comparable intensities of the house keeping
eukaryotic elongation factor 1a (eEF1a) band. Higher level
of ALCAM in THP1 monocytes compared to HL60 mono-
cytes, as well as the relatively low-level ALCAM expression
in U937 cells were conﬁrmed in multiple experiments. Treat-
ment of cell lysates with PNGase F reduced the size of AL-
CAM in each monocyte cell line to an immunoreactive
protein band of 70 kDa (data not shown). Next, we demon-
strated by ﬂow cytometry using FITC labeled anti-human AL-
CAM antibody J4-81, and MOG/07 that ALCAM was
expressed on the surface of THP1 and HL60 cells (Fig. 1D
and data not shown). These data demonstrated more wide-
spread expression, and appropriate post-translational regula-
tion of ALCAM in human monocyte cell lines, and
therefore, these cells were used to evaluate ALCAM’s role in
monocyte–endothelial interactions.
3.2. ALCAM is involved in transmigration of monocytes across
PMVECs
Leukocyte retention and recruitment occurs in the pulmon-
ary capillary bed [4,5]. We and others have extensively studied
PMVECs isolated from this vascular segment [28,29,32,33]
however there is a paucity of data on monocyte transmigrationacross this endothelium. Single cell suspension of PMVECs was
seeded on ﬂuorescent blocking transwell inserts and cultured
for 4–5 days, creating an endothelial monolayer that was virtu-
ally impermeable to 70 kDa dextran solutes (less than 5% per-
meability, data not shown). THP1 cells were labeled with
calcein-AM and added to the upper chamber of the insert.
Fluorescence intensity at the bottom of the insert, representing
the number of cells that had crossed the endothelial monolayer,
was measured at multiple time intervals at 37 C for 3 h. There
was a linear relationship between ﬂuorescence intensity and
number of THP1 cells (R2 = 0.997) (Fig. 2A). Moreover, the
presence of monocyte chemoattractant protein-1 (MCP-1) in
the lower chamber dose-dependently increased the number of
THP1 cells that transmigrated across the PMVEC barrier
(Fig. 2B). These results demonstrated that our assay supported
transendothelial monocyte migration and was therefore suit-
able for studying the role of ALCAM in this process.
Fig. 2C shows typical proﬁles of THP1 cell transendothelial
migrations performed in the presence or absence of soluble re-
combinant human ALCAM (ALCAM-Fc). Several studies
have previously shown that soluble ALCAM-Fc inhibits AL-
CAM-mediated cell adhesions [18,24,34], and the preparation
used in this study was conﬁrmed by mass spectrometry to be
highly pure (data not shown). Transmigration was reduced by
50% in experiments performed in the presence of recombinant
human ALCAM-Fc (25 lg/ml) (Fig. 2D). Importantly, re-
combinant human ALCAM-Fc inhibited transendothelial
migration in experiments performed with HL60 cells, indicat-
ing the phenomenon we observed with THP1 was not a pecu-
liarity of that monocyte cell line (Fig. 2D). The inhibitory
eﬀect of recombinant soluble ALCAM was evident early
and persisted throughout the duration of the assay
(Fig. 2C). The assay used in this study permitted real-time
evaluation of the number of cells migrating through the endo-
thelial barrier therefore we were able to obtain kinetic infor-
mation on the same population of monocytes traversing the
same endothelial monolayer. This data consistently showed
ﬂuctuations in the rate of transmigration (Fig. 2C). Impor-
tantly, recombinant human ALCAM-Fc did not change the
shape of the transmigration curve suggesting the inhibitory ef-
fect we observed reﬂected downregulation of a normal mech-
anism of monocyte transendothelial migration. In control
experiments with recombinant human chimeric Fc protein
(VE-cadherin-Fc, 25 lg/ml) no eﬀect on transmigration was
identiﬁed. This indicates ALCAM-binding molecules on the
monocyte cell lines used in this study are involved in transen-
dothelial migration.
To test whether ALCAM was directly responsible for the
above transendothelial migrations, various anti-ALCAM anti-
bodies were used to block ALCAM prior to the transmigration
assay. Anti-human ALCAM monoclonal antibody J4-81 has
previously been demonstrated to block ALCAM mediated
functions including proliferation and adhesion [23,35]. When
THP1 cells were treated with this antibody, it blocked transmi-
gration by 70%, when compared to experiments performed
without any antibody (Fig. 2E). Importantly, J4-81 Fab frag-
ments inhibited transmigration by a similar margin indicating
this was a speciﬁc function blocking phenomenon, and not a
non-speciﬁc eﬀect due to potential cross-linking of Fc tails
(Fig. 2E). MOG/07 and BRI-1 had relatively modest eﬀects,
whereas anti-rat ALCAM monoclonal 2117 and mouse IgG
had no signiﬁcant impact on transmigration (Fig. 2E). Expres-
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Fig. 2. ALCAM is involved in transendothelial monocyte migration. Fluroblock inserts with 3 lm pores were seeded with PMVECs and conﬂuent
endothelial monolayers used for transmigration assays. (A) Standard curve showing linear relationship between ﬂuorescence intensity and number of
calcein-AM labeled THP1 monocytes. (B) MCP-1 dose-dependently increased the number of THP1 monocytes that migrated across the endothelial
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competitor (control and ﬁlled triangle), recombinant human ALCAM-Fc (open box) and recombinant human chimeric Fc-control (ﬁlled box). MCP-
1 (10 ng/ml) was used as chemoattractant. (D) Quantitative data from experiments similar to that shown in Fig. 3C, showing inhibition of
transendothelial migration by ALCAM-Fc (25 lg/ml) and lack of eﬀect in control experiments (No competitor, and Fc-control). Data shown is the
mean number of THP1 and HL60 monocytes that transmigrated for 3 h in three independent experiments. **P < 0.001, *P < 0.05. (E) THP1
monocytes were incubated with 20 lg of J4-81, J4-81 Fab fragments, MOG/07, 2117 and mouse IgG or BRI-1 polyclonal antibody (1:100 dilution)
for 30 min. Unbound antibody was washed away, and cells used for transmigration. Blocking ALCAM with J4-81 Fab fragments blocked
transmigration as eﬃciently as when the antibody was used intact. Data shown are the mean number of THP1 monocytes that transmigrated for 3 h
in three independent experiments of three replicates. ***P < 0.0001, *P < 0.05.
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to thymocytes, mature T cells, and a small subset of B cells
known as B-1 cells [36], and more importantly monocytes lack
CD6 expression [37]. Therefore, it is reasonable to conclude
that homotypic ALCAM adhesion is primarily responsible
for the ALCAM-mediated transendothelial migration reported
in this study. ALCAM expression is well characterized in acti-
vated primary monocytes and monocyte cell lines, as well as in
a small subset of B-cells [21,23]. More recent studies have re-
ported ALCAM expression in circulating dendritic cells [35],
and several groups have identiﬁed ALCAM as a surface mar-
ker of mesenchymal stem cells [24,38–40]. Therefore, ALCAM
may be involved in regulating transmigration of diverse cell
types across various biological barriers.
3.3. Binding of rat and human ALCAM
The above transendothelial migration data suggested there
was functional binding between human and rat ALCAM. Se-
quence alignment revealed a 95.8% amino acid identity in
the N-terminal Ig ligand binding domain (D1), which mediates
homotypic ALCAM adhesion (Fig. 3A). This strongly sug-
gested there was conservation of the ligand binding propertiesof human and rat ALCAM. Since recombinant human AL-
CAM-Fc was used throughout this study, we created recombi-
nant rat ALCAM fused to green ﬂuorescent protein (GFP) to
examine binding between the two ALCAM species. We have
extensive experience with the human K562 cell line [41–43],
which according to several previous studies lacks endogenous
ALCAM expression [23,44]. Indeed, ALCAM was not de-
tected in K562 cells by Western blot analysis in this study
(Fig. 1C). Parental K562 cells cluster during log-phase growth,
nonetheless it was evident more clusters of larger sizes formed
in stable K562 cells expressing rat ALCAM-GFP, and more-
over ALCAM-GFP was recruited to sites of cell–cell contact
(Fig. 3B and data not shown). To test whether rat ALCAM
binds human ALCAM, recombinant human ALCAM-Fc
was used to coat the bottom of 96-well plates. Single cell sus-
pensions of K562-ALCAM-GFP and control K562-GFP cells
were loaded unto recombinant human ALCAM-Fc or BSA
coated surfaces, and the number of cells remaining adherent
determined by ﬂuorescence intensity. Nearly 18% of stable
K562-ALCAM-GFP cells consistently remained attached to
recombinant human ALCAM-Fc, compared to the back-
ground binding (less than 2.5%) observed for parental K562
Fig. 3. Binding between rat and human ALCAM. (A) Alignment of the ligand binding N-terminal Ig domain of rat and human ALCAM shows
greater than 95% amino acid sequence identity. (B) Cluster of two human K562 cells expressing rat-ALCAM fused to GFP. (i) Outline of the two
cells and four consecutive z-sections (ii)–(v) showing localization of ALCAM-GFP in the plasma membrane with enrichment at sites of cell–cell
contact. The outline shown in (i) is for cells in the z-section shown in (iii). Bar 25 lm. (C) Stable K562 cells were labeled with calcein-AM and allowed
to adhere to immobilized recombinant human ALCAM-Fc (rhALCAM-Fc) at 37 C for 1 h. Percentage of adhering cells was determined by
ﬂuorescence intensity detected by excitation at 490 nm with bandwidth of 5 nm, and emission at 510 nm with a bandwidth of 5 nm a using a bottom
reading ﬂuorescent plate reader. Data shown are the mean percentage of cells remaining adherent to immobilized ALCAM ligand in three
independent experiments each of eight replicates.
2642 A. Masedunskas et al. / FEBS Letters 580 (2006) 2637–2645and stable K562-GFP cells (Fig. 3C and data not shown). Sim-
ilar results were obtained when recombinant mouse ALCAM-
Fc was used as the immobilized ligand (data not shown). These
data provide direct evidence of ligand binding between human
ALCAM and its rat orthologue, and supports the contention
that homotypic ALCAM adhesion contributed to the transen-
dothelial monocyte migration reported in Fig. 2.
3.4. ALCAM is not involved in THP1 migration or adhesion to
endothelium
It was unclear from the data presented in Figs. 2 and 3
whether ALCAM was involved in diapedesis or ﬁrm adhesion
of monocytes to endothelium. To investigate the latter more
speciﬁcally, THP1 cells were labeled with calcein-AM and
co-incubated with conﬂuent PMVEC monolayers, seeded on
non porous surfaces in 96-well culture plates, in the presence
or absence of recombinant human ALCAM-Fc (25 lg/ml).
Thereafter, the co-culture was gently rinsed with PBS, and
the number of cells adherent to the endothelial monolayer
measured by ﬂuorescence intensity. Typically, 40% of THP1
cells remained attached to the endothelium (Fig. 4A). Multiple
adhesion assays showed that recombinant human ALCAM-Fc
did not alter the percentage of THP1 cells that remained at-
tached to the PMVEC monolayer (Fig. 4A). To verify thatour assay was capable of detecting alterations in THP1 adhe-
sion to endothelium, PMVEC monolayers were pre-treated
with tumor necrosis factor a (TNF-a) for 24 h prior to the
adhesion assay. Percentage of THP1 cells adherent to TNF-
a-treated monolayers increased by 50%, however, ALCAM-
Fc had no impact on adhesion (data not shown). Next, we
determined whether ALCAM was involved in migration of
THP1 monocytes in the absence of an endothelial barrier using
the Transwell approach. Signiﬁcantly more (45% more cells)
THP1 cells migrated towards MCP-1 in the absence of an
endothelial barrier (data not shown). However, there was no
statistical diﬀerence in the number of cells that migrated in
experiments performed in the presence or absence of recombi-
nant human ALCAM-Fc (Fig. 4B and C).
ALCAM has been implicated in motility of endothelial cells
and melanoma cells by several groups using the same commer-
cially available recombinant ALCAM-Fc employed in this
study to block cell-mediated adhesion [18,24,26,27]. More re-
cently, a truncated soluble ALCAM variant consisting of the
N-terminal ligand binding domain alone, reportedly enhanced
migration of individual endothelial cells although this reagent
had no impact on endothelial sheet migration [45]. It was there-
fore surprising to ﬁnd no role for ALCAM in migration of
THP1 cells in this study. Recent data suggests that mature den-
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Fig. 4. ALCAM is not involved in monocyte–endothelial adhesion or monocyte migration. (A) Adhesion of calcein-AM labeled THP1 monocytes to
PMVEC monolayer in the presence or absence of recombinant human ALCAM-Fc (25 lg/ml). Data shown are the mean percentage of cells
remaining adherent to the endothelium in three independent experiments each of at least eight replicates. (B) Typical migration proﬁle of THP1 cells
moving through Fluroblock inserts with 3 lm pores towards MCP-1 (10 ng/ml) in the lower chamber. (C) Quantitative data showing THP1 cell
migration in the presence and absence of recombinant human ALCAM-Fc (25 lg/ml). Data shown are the mean number of THP1 cells that migrated
for three hours in four independent experiments each of three replicates.
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organization [35], therefore we cannot exclude the possibility
that a hitherto unknown modiﬁcation of ALCAM plays a role
in migration of macrophages and dendritic cells, which are
more diﬀerentiated than the monocytic cells used in this study.
3.5. ALCAM is located in the lateral plasma membrane domain
in endothelial cells
Functional data in Figs. 2 and 4 suggested ALCAM was
localized at sites in the endothelium speciﬁcally involved in
diapedesis. We demonstrated by western blot analysis the pres-Fig. 5. ALCAM is located at endothelial cell junctions. (A). Western blot ana
microscopic photo sections of PMVECs labeled for ALCAM. Images shown
focal intervals (3 of 16 shown here). (C). Confocal z-plane of conﬂuent PMVE
ALCAM-GFP (green) localizes to sites of cell–cell contact in transfected PM
cell junctions as shown in the merged image (iii). Bar 50 lm.ence of fully mature ALCAM in cultured PMVECs (Fig. 5A).
Fig. 5B is a panel of confocal lateral photosegments of cul-
tured PMVECs labeled for ALCAM. It shows enrichment of
ALCAM in basolateral membrane segments, and sparse label-
ing in apical and basal domains of the plasma membrane. This
sub-cellular localization was conﬁrmed in independent experi-
ments in which both xy and zy-planes of conﬂuent PMVEC
monolayers were analyzed by confocal microscopy, and the
data showed ALCAM localization in the lateral plasma mem-
brane domain in endothelium (Fig. 5C), which is consistent
with a functional role for ALCAM in diapedesis. Treatmentlysis showing expression of mature ALCAM in PMVECs. (B) Confocal
here represent apical, basolateral and basal segments taken at 0.3 lm
Cs showing ALCAM labeling in lateral plasma membrane domain. (D)
VECs (i), and co-localizes with endogenous ALCAM (ii) at endothelial
2644 A. Masedunskas et al. / FEBS Letters 580 (2006) 2637–2645of conﬂuent PMVECs with a concentration range (0.5–5 mM)
of EGTA delocalized ALCAM from cell junctions, and a puta-
tive interaction between ALCAM and the actin cytoskeleton
was conﬁrmed by delocalization of the molecule from the
endothelial junction following treatment of conﬂuent
PMVECs with cytochalasin D (data not shown).
The above data in Fig. 5B and C and experiments with cyto-
chalasin D and EGTA (data not shown) were consistent with
recruitment of ALCAM to endothelial cell junctions. Indeed,
when PMVECs were transiently transfected with rat AL-
CAM-GFP vector, ALCAM-GFP was recruited to intercellu-
lar junctions in conﬂuent endothelial cultures (Fig. 5Di).
Authenticity of the ALCAMmolecule expressed by this chime-
ric construct was conﬁrmed by staining endothelial transfec-
tants with aﬃnity puriﬁed BRI-1. Fig. 5Dii shows there is
more intense staining of ALCAM in cells expressing AL-
CAM-GFP compared to cells exclusively expressing endoge-
nous ALCAM. Importantly, ALCAM-GFP behaved exactly
like the endogenous protein, and was recruited to endothelial
cell junctions.
The central ﬁnding in this study is that ALCAM is recruited
to the lateral plasma membrane domain in endothelial cells,
and at least partially controls diapedesis of ALCAM-positive
cells such as the monocyte cell lines used in this study. AL-
CAM-Fc (25 lg/ml) reduced transmigration by 50%, and while
increasing the concentration of ALCAM-Fc to 50 lg/ml did
not provide additional inhibition, a lower concentration
(5 lg/ml) had an intermediate inhibitory eﬀect blocking trans-
migration by 33% (data not shown). Direct evidence for AL-
CAM’s role in transendothelial migration was provided by
experiments using anti-ALCAM antibody, which revealed
inhibition of this process by up to 70%. Since monocytes do
not express CD6 [37], the only other known ALCAM ligand,
it is reasonable to conclude from these data that homotypic
ALCAM-adhesion is responsible for ALCAM-mediated dia-
pedesis. Recent cloning of soluble ALCAM suggests the func-
tional attributes reported for ALCAM and its soluble variant
in this study may be physiologically relevant. Interestingly,
TNF-a increases soluble ALCAM expression without altering
membrane bound ALCAM expression in endothelial cells [45].
Since this cytokine is produced early in the inﬂammatory re-
sponse, future studies will test the hypothesis that soluble AL-
CAM inhibits ALCAM-mediated monocyte recruitment early
in the inﬂammatory response to speciﬁcally prevent premature
accumulation of tissue macrophages.
The sub-cellular localization of ALCAM in endothelial cells
was readily disrupted by subtly disturbing the actin cytoskele-
ton, and produced a phenotype similar to that reported previ-
ously in K562 cells expressing heterologous ALCAM [44,46].
The scaﬀolding molecule responsible for the interaction be-
tween ALCAM and the cytoskeleton remains enigmatic.
Recruitment of ALCAM-GFP to endothelial cell junctions in
live cells oﬀers a powerful in vivo approach to validate physical
coupling between ALCAM and candidate scaﬀold proteins in
future studies. In conclusion, this study provides the ﬁrst evi-
dence to support a novel concept that ALCAM is a component
of the endothelial cell junction and a member of the molecular
machinery controlling diapedesis.
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